Yuichi Takatsuka

2.3k total citations
91 papers, 1.7k citations indexed

About

Yuichi Takatsuka is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Yuichi Takatsuka has authored 91 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 46 papers in Cancer Research and 19 papers in Pathology and Forensic Medicine. Recurrent topics in Yuichi Takatsuka's work include Breast Cancer Treatment Studies (43 papers), Cancer Treatment and Pharmacology (23 papers) and HER2/EGFR in Cancer Research (18 papers). Yuichi Takatsuka is often cited by papers focused on Breast Cancer Treatment Studies (43 papers), Cancer Treatment and Pharmacology (23 papers) and HER2/EGFR in Cancer Research (18 papers). Yuichi Takatsuka collaborates with scholars based in Japan, United States and Switzerland. Yuichi Takatsuka's co-authors include Shinzaburo Noguchi, Luigi Cataliotti, Pierre Dubé, Aman U. Buzdar, Tomohiko Aihara, José Bines, Katarína Petráková, Célia Tosello Oliveira, Hideo Morino and Nobuteru Kikkawa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Power Sources.

In The Last Decade

Yuichi Takatsuka

86 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuichi Takatsuka Japan	22	940	707	371	306	276	91	1.7k
M Francoual France	28	1.5k 1.6×	327 0.5×	137 0.4×	729 2.4×	305 1.1×	60	2.2k
G. N. Hortobágyi United States	23	1.7k 1.9×	962 1.4×	176 0.5×	573 1.9×	311 1.1×	106	2.7k
Laura Orlando Italy	27	1.9k 2.0×	1.3k 1.9×	321 0.9×	946 3.1×	341 1.2×	92	2.9k
Marie‐Christine Mathieu France	25	978 1.0×	705 1.0×	212 0.6×	461 1.5×	445 1.6×	63	2.1k
Silvia Dellapasqua Italy	25	1.1k 1.2×	1.1k 1.5×	217 0.6×	458 1.5×	334 1.2×	55	1.8k
Marie-Christine Étienne-Grimaldi France	27	1.3k 1.4×	343 0.5×	68 0.2×	722 2.4×	242 0.9×	82	1.9k
G. Peruzzotti Italy	20	1.3k 1.4×	1.2k 1.7×	232 0.6×	460 1.5×	428 1.6×	44	2.1k
Kuk Jin Choe South Korea	25	926 1.0×	458 0.6×	244 0.7×	447 1.5×	380 1.4×	71	2.0k
Peter Ang Singapore	21	730 0.8×	214 0.3×	357 1.0×	469 1.5×	110 0.4×	57	1.6k
Masataka Yoshimoto Japan	26	810 0.9×	734 1.0×	380 1.0×	630 2.1×	518 1.9×	84	1.8k

Countries citing papers authored by Yuichi Takatsuka

Since Specialization

Citations

This map shows the geographic impact of Yuichi Takatsuka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichi Takatsuka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichi Takatsuka more than expected).

Fields of papers citing papers by Yuichi Takatsuka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichi Takatsuka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichi Takatsuka. The network helps show where Yuichi Takatsuka may publish in the future.

Co-authorship network of co-authors of Yuichi Takatsuka

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichi Takatsuka. A scholar is included among the top collaborators of Yuichi Takatsuka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichi Takatsuka. Yuichi Takatsuka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nagahashi, Masayuki, Eri Ishikawa, Takahiro Nagai, et al.. (2025). Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer. 32(2). 404–415.

Imamura, Michiko, Takashi Morimoto, Takashi Nomura, et al.. (2018). Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World Journal of Surgical Oncology. 16(1). 26–26. 21 indexed citations

Miyagawa, Yoshimasa, Kazuhiro Araki, Yukie Fujimoto, et al.. (2018). Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel. Clinical Breast Cancer. 18(5). 400–409. 44 indexed citations

Imamura, Michiko, Arisa Nishimukai, Tomoko Higuchi, et al.. (2015). High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. Breast Cancer Research and Treatment. 154(3). 521–531. 5 indexed citations

Matsuda, Ikuo, et al.. (2014). Spontaneous regression of primary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) colliding with invasive ductal carcinoma of the breast: a case report.. PubMed Central. 7(10). 7020–7. 2 indexed citations

Yagi, Tomoko, Natsuko Inoue, Ayako Yanai, et al.. (2014). Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 23(2). 224–230. 10 indexed citations

Nishimukai, Arisa, Tomoko Yagi, Ayako Yanai, et al.. (2014). High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer. 15(3). 204–211. 35 indexed citations

Miyake, Tomohiro, Takashi Ito, Ayako Yanai, et al.. (2013). C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis. Breast Cancer. 22(4). 366–373. 6 indexed citations

Miyagawa, Yoshimasa, Tomohiro Miyake, Ayako Yanai, et al.. (2013). Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. Breast Cancer. 22(4). 399–405. 11 indexed citations

10.

Suzuki, Yasuhiro, Toshiaki Saeki, Kenjiro Aogi, et al.. (2012). A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. International Journal of Clinical Oncology. 18(4). 590–597. 4 indexed citations

11.

Fujiwara, Yasuhiro, Yuichi Takatsuka, Shigeru Imoto, et al.. (2011). Outcomes of Japanese breast cancer patients treated with pre‐operative and post‐operative anastrozole or tamoxifen. Cancer Science. 103(3). 491–496. 3 indexed citations

12.

Kimura, Morihiko, Takeshi Tominaga, Yuichi Takatsuka, et al.. (2009). Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer. 17(3). 190–198. 5 indexed citations

13.

Ishida, Takanori, Takayoshi Kiba, Motohiro Takeda, et al.. (2008). Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemotherapy and Pharmacology. 64(2). 361–369. 28 indexed citations

14.

Toi, Masakazu, Seigo Nakamura, Katsumasa Kuroi, et al.. (2007). Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Research and Treatment. 110(3). 531–539. 94 indexed citations

15.

Iwata, Hiroji, Seigo Nakamura, Masakazu Toi, et al.. (2005). Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. Breast Cancer. 12(2). 99–103. 17 indexed citations

16.

Aihara, Tomohiko, Yuichi Takatsuka, Kuniaki Itoh, et al.. (2003). Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer. Oncology. 64(2). 124–130. 10 indexed citations

17.

Miki, Hirofumi, Shigeyuki Tamura, Hiroshi Wada, et al.. (2003). [A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].. PubMed. 30(11). 1661–4. 1 indexed citations

18.

Tono, Takeshi, Yasunori Hasuike, Hiroki Ohzato, Yuichi Takatsuka, & Nobuteru Kikkawa. (2000). Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Cancer. 88(7). 1549–1556. 63 indexed citations

19.

Tono, Takeshi, Nobuteru Kikkawa, Hideyuki Mishima, et al.. (1995). The Significance of Second Hepatectomy for Recurrent Metastases from Colorectal Primaries.. The Japanese Journal of Gastroenterological Surgery. 28(3). 662–666. 2 indexed citations

20.

Takatsuka, Yuichi, et al.. (1986). A SUSPECTED CASE OF OCCULT CARCINOMA OF THE BREAST. The journal of the Japanese Practical Surgeon Society. 47(2). 195–198. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact